NCT01240876 - Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

April 30, 2013

Conditions

Sciatica

Interventions

DRUG

CEP-37247

0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.

DRUG

Placebo

Matching placebo vials will be filled with the buffered solution for CEP-37247.

Trial Locations (24)

Teva Investigational Site 22, La Mesa

Teva Investigational Site 18, Laguna Hills

Teva Investigational Site 19, Pasadena

Teva Investigational Site 2, Pasadena

Teva Investigational Site 14, Orlando

Teva Investigational Site 5, Sarasota

Teva Investigational Site 10, Marietta

Teva Investigational Site 13, Marietta

Teva Investigational Site 9, Bloomington

Teva Investigational Site 15, Overland Park

Teva Investigational Site 8, Shreveport

Teva Investigational Site 20, Winston-Salem

Teva Investigational Site 16, Dayton

Teva Investigational Site 21, Eugene

Teva Investigational Site 17, Altoona

Teva Investigational Site 1, Greenville

Teva Investigational Site 11, North Charleston

Teva Investigational Site 6, Spartanburg

Teva Investigational Site 4, Orem

Teva Investigational Site 3, Salt Lake City

Teva Investigational Site 103, Caulfied South

Teva Investigational Site 102, Malvern East

Teva Investigational Site 100, North Terrace

Teva Investigational Site 101, St Leonards